Phase 2 Pancreatic Cancer Trial, Recruiting NCT06605430 Sponsor: HealthPartners Institute Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06605430
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older at the time of enrollment
  • People who have been diagnosed with pancreatic or colorectal cancer confirmed through a tissue or cell sample (note: neuroendocrine tumors of the pancreas or colon are not included)
  • People whose cancer is at an advanced stage — either spread to nearby areas or to other parts of the body — with no plans for surgery aimed at curing the cancer in the next 3 months
  • People who have experienced at least one of the following in the past 14 days: nausea, vomiting, loss of appetite, unintended weight loss/muscle wasting, or pain
  • People who are about to start, or have started within the past 2 weeks, standard chemotherapy (not including immunotherapy) at a participating clinic, and who have not had any systemic cancer treatment in the past 3 months (prior chemotherapy given before or after surgery is allowed if it was more than 3 months ago)
  • People who currently live in Minnesota
  • People who are willing to register with the Minnesota Medical Cannabis Program and follow all of its rules
  • People who are willing to complete surveys about their symptoms and health at required points during the trial

Who may not be able to join:

  • People who have regularly used a cannabis product containing THC — meaning 10 or more days in the past 30 days
  • People who have previously had a bad reaction or sensitivity to cannabis (for example, cannabis hyperemesis syndrome, which is severe vomiting caused by cannabis use)
  • People who have Alzheimer's disease, active epilepsy, or a history of traumatic brain injury
  • People who have known cancer that has spread to the brain and is active or untreated
  • People who are receiving immunotherapy, a combination of chemotherapy and immunotherapy, non-standard chemotherapy, or who are taking part in another clinical trial involving an experimental cancer treatment
  • Women who are pregnant, breastfeeding, or able to become pregnant and not using birth control
  • People with serious uncontrolled medical or psychiatric conditions, or significant abnormal lab results, that the trial doctor believes could make participation unsafe or affect the trial's results (confirm with trial site)
  • People with any other condition that the trial doctor believes could affect their safety or their ability to follow the trial's requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (952) 977-5555

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
HealthPartners Institute
Registry
ClinicalTrials.gov
Start date
16 September 2024
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assess feasibility for conducting a larger randomized trial by determining rate of recruitment, compliance with randomization group, and protocol adherence to this clinical trial.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov